Evaluation of KX2-391 in Patients With Advanced Malignancies

Inclusion Criteria: * Signed written informed consent * Adults over age 18 years of age * Confirmed advanced solid tumor or lymphoma that may be metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; patients with treated brain or ocular metastases are also eligible * ECOG performance status of 0-2 * Life expectancy of at least 14 weeks * Adequate bone marrow reserve * Adequate liver function as demonstrated by serum bilirubin, alanine aminotransferase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) * Adequate renal function (serum creatinine \</= 1.5 x ULN or calculated creatinine clearance \> 60 ml/min) * Normal coagulation profile (PT/INR and aPTT within institutional normal limits) for those who give consent to tumor biopsy, within 1 week prior to the procedure. * Negative pregnancy test for females at Screening, preferably done within 1 week before Day 1 of dosing (not applicable to patients with bilateral oophorectomy and/or hysterectomy) * Willing to abstain from sexual activity or practice physical barrier contraception 28 days before Day 1 of dosing and 6 months after the last dose for the patient * Signed written informed consent for tumor biopsy for the additional 10 subjects that will be dosed at the MTD and who have accessible tumors Exclusion Criteria: * Unresolved toxicity of higher than Grade 1 severity from previous anti-cancer treatment or investigational agents * Recei…